The company operates as a non-banking financial company (NBFC) primarily engaged in providing loans and advances to corporate entities and trading in equity shares.
The company lacks any identifiable competitive advantage, as evidenced by extremely low average ROCE of 0.5% and negative net margins. The business model relies on unsecured corporate lending and share trading, which are highly commoditized and subject to significant market volatility.
Historical capital allocation has been poor, with capital largely tied up in non-productive assets or low-yield loans. The recent massive increase in borrowing limits to 500 Crores and preferential allotments suggests a shift toward aggressive expansion or debt-to-equity swaps rather than organic value creation.
The company's aggressive expansion into unsecured corporate lending, fueled by a five-fold increase in borrowing limits, likely collapsed under the weight of poor credit quality and non-performing assets. The sudden revenue surge proved to be a mirage of low-quality 'Other Income' and share trading gains rather than sustainable operations. As management turnover continued and regulatory scrutiny intensified due to historical non-compliance, the lack of an audit trail and qualified financial reporting eventually led to a total loss of investor confidence and a liquidity crunch.
RichFakir rates Corporate Merchant Bankers Ltd's business quality as poor — 28/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Corporate Merchant Bankers Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Corporate Merchant Bankers Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Corporate Merchant Bankers Ltd's fair value is about ₹3 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →